Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression-Reference-Cited by-同舟云学术

Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression

Published:2020-03-30 Issue:20 Volume:39 Page:4077-4091
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Chandrashekar Darshan S.,Chakravarthi Balabhadrapatruni V. S. K.,Robinson Alyncia D.,Anderson Joshua C.^ORCID,Agarwal Sumit,Balasubramanya Sai Akshaya Hodigere,Eich Marie-Lisa,Bajpai Akhilesh Kumar,Davuluri Sravanthi,Guru Maya S.,Guru Arjun S.,Naik Gurudatta,Della Manna Deborah L.,Acharya Kshitish K.,Carskadon Shannon,Manne Upender,Crossman David K.^ORCID,Ferguson James E.,Grizzle William E.,Palanisamy Nallasivam,Willey Christopher D.,Crowley Michael R.,Netto George J.^ORCID,Yang Eddy S.,Varambally Sooryanarayana,Sonpavde Guru

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/s41388-020-1275-7.pdf

Reference80 articles.

1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96–108.

2. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–8.

3. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl J Med. 2003;349:859–66.

4. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171–7.

5. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67–76.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response;EBIOMEDICINE;2024

2. Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response;eBioMedicine;2024-06

3. Inhibition of Erb-B2 Receptor Tyrosine Kinase 3 and Associated Regulatory Pathways Potently Impairs Malignant Peripheral Nerve Sheath Tumor Proliferation and Survival;The American Journal of Pathology;2023-09

4. Circ_0000235 targets MCT4 to promote glycolysis and progression of bladder cancer by sponging miR-330-5p;Cell Death Discovery;2023-08-02

5. Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma;Heliyon;2023-08